Institutional Holdings Increase
Aptus Capital Advisors and Institutional Peers Expand Holdings in Key ETFs and Stocks
Key Points
For the JPMorgan BetaBuilders International Equity ETF (BBIN), Aptus reported buying 52,463 shares in Q4 to reach 594,360 shares total, valuing the position at $42,984,000 in its latest SEC filing.
In BBIN, Morgan Stanley’s increase was substantially larger than other reported investors: it lifted its stake by 61.2% in Q4, to 3,574,797 shares worth $258,529,000 (after adding 1,357,830 shares).
For AbbVie (ABBV), the filings included detailed roll-ups of other major holders: Vanguard Group owned 177,747,261 shares worth $41,155,601,000 after adding 448,554 shares in the last quarter, and institutional ownership was cited at 70.23%.
Johnson & Johnson’s recent corporate action was also highlighted: the company announced a quarterly dividend of $1.34 per share, with stockholders of record on May 26 and the dividend paid on June 9.
In IBM (IBM), the article noted that 58.96% of the stock is owned by hedge funds and other institutional investors, and pointed to at least one new position: Burton Enright Welch purchased a new IBM position in Q4 valued at about $392,000.
Aptus Capital Advisors LLC added 52,463 shares of the JPMorgan BetaBuilders International Equity ETF (BBIN) in the fourth quarter, bringing its total stake to 594,360 shares worth $42,984,000, according to Defense World. The move is part of a broader push by the Alabama-based firm to build exposure across international equities, healthcare, and technology.
Aptus was not alone. Morgan Stanley made a far bigger move in the same ETF, adding 1,357,830 shares — a 61.2% increase — to reach 3,574,797 shares valued at $258,529,000, per Ticker Report.
Morgan Stanley Dwarfs Aptus in BBIN Accumulation
BBIN tracks developed markets outside North America, including Europe and Asia. It carries a low fee of just 7 basis points, making it a cheap way for institutions to hedge against U.S. market concentration. Aptus's $43 million position is notable, but Morgan Stanley's $258.5 million stake shows the depth of institutional interest in the fund, according to Ticker Report.
Some analysts see the move as institutions "front-running a potential dollar weakening," as U.S. tech valuations hit historic highs. The simultaneous accumulation by multiple large firms signals that the international equity trade is gaining momentum heading into mid-2026.
Aptus Lifts AbbVie and J&J Stakes in Healthcare Bet
Aptus added 2,358 shares of AbbVie (ABBV) in Q4, a 1.7% increase, bringing its total to 137,505 shares, according to Ticker Report. Vanguard Group remains the dominant holder, owning 177,747,261 shares worth $41,155,601,000 after adding 448,554 shares. Overall, institutions own 70.23% of AbbVie's outstanding stock.
Aptus also raised its Johnson & Johnson (JNJ) position by roughly 21%. J&J recently declared a quarterly dividend of $1.34 per share. Stockholders of record on May 26 received the payment on June 9. The move came after J&J completed its spin-off of its consumer health unit, Kenvue, leaving it focused purely on pharmaceuticals and medical devices.
IBM Position Grows as AI Narrative Reaches Smaller Advisors
Aptus grew its IBM stake by about 2.9% in Q4. Institutional and hedge fund investors own 58.96% of IBM's stock, per Watchlist News. A smaller firm, Burton Enright Welch, also opened a brand-new IBM position in Q4 worth roughly $392,000. That signals the AI and cloud story at IBM is now reaching independent wealth advisors, not just Wall Street giants.
IBM has spent the past decade shifting from legacy hardware to hybrid cloud and artificial intelligence through its WatsonX platform. If IBM's next earnings report shows double-digit growth in AI consulting, institutional ownership could cross 60% — a shift that would move the stock from a pure "value" label to a growth-at-a-reasonable-price play.
Why Institutions Keep Piling Into Dividend-Heavy Names
The pattern across ABBV, JNJ, and IBM points to a "quality rally" strategy. Firms like Aptus and Vanguard are betting on strong balance sheets and steady dividend income. AbbVie's 70.23% institutional ownership acts as a built-in volatility buffer, even as the company manages the fallout from Humira losing patent protection and facing cheaper biosimilar rivals.
For J&J, the $1.34 quarterly dividend — roughly a 3% annualized yield — gives institutional holders a reliable income floor. High institutional concentration also means pressure on management to protect that payout. Any cut to the dividend could trigger a wave of forced selling across dozens of large funds simultaneously, according to Ticker Report.
Sentiment
Mostly PositivePublishers
30
Articles
14
Reach
44
